Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03262610 · ClinicalTrials.gov registry record · Phase 2
Setmelanotide in a Single Patient With Partial Lipodystrophy
A Phase 2 study, sponsored by Rhythm Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT03262610: Completed Phase 2 study, sponsored by Rhythm Pharmaceuticals.
NCT03262610 is a Phase 2 study that has completed, run by Rhythm Pharmaceuticals. The registered enrollment target is 1 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03262610, a Phase 2 study, has completed, sponsored by Rhythm Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
The objective of this single patient study is to assess the safety and efficacy of setmelanotide as a treatment of severe metabolic abnormalities resulting from LD, especially refractory hypertriglyceridemia leading to recurrent bouts of pancreatitis.
Primary Outcome
The mean change from baseline in fasting triglycerides after setmelanotide treatment.
Interventions
- DRUG Setmelanotide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-08-15 |
| Est. Completion | 2018-01-31 |
| Phase | Phase 2 |
What the finished NCT03262610 record still lists
NCT03262610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which Setmelanotide is the first listed.
NCT03262610 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03262610 about?
NCT03262610 is a clinical study titled "Setmelanotide in a Single Patient With Partial Lipodystrophy". The objective of this single patient study is to assess the safety and efficacy of setmelanotide as a treatment of severe metabolic abnormalities resulting from LD, especially refractory hypertriglyceridemia leading to recurrent bouts of pancreatitis.
What is the current status of trial NCT03262610?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2017-08-15. Estimated completion is 2018-01-31.
What interventions are being tested in trial NCT03262610?
The interventions under investigation include: Setmelanotide (DRUG).
Who is sponsoring clinical trial NCT03262610?
This trial is sponsored by Rhythm Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03262610's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI